OptimizeRx OPRX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 67.3%+27.0pp | 40.3%-19.7pp | 60%-2.4pp | 62.4%+4.3pp | |
| Operating margin | 10.7%— | —— | -36.9%-17.2pp | -19.7%-20.3pp | |
| Net margin | 4.7%+41.4pp | -36.7%-12.1pp | -24.6%-6.2pp | -18.3%-18.9pp | |
| Returns | |||||
| Return on equity | 4.2%+20.7pp | -16.5%-2.6pp | -13.9%-5.0pp | -8.9%-9.3pp | |
| Return on invested capital | 6.4%— | —— | -20.5%-4.6pp | -15.8%-16.7pp | |
| Efficiency | |||||
| Asset turnover | 0.6×+0.3× | 0.3×-0.1× | 0.4×0.0× | 0.5×-0.2× | |
| Liquidity | |||||
| Current ratio | 3×+0.2× | 2.9×-0.1× | 3×-8.7× | 11.7×-0.5× | |
| Leverage | |||||
| Debt-to-equity | 0.2×-0.1× | 0.3×0.0× | 0.3×+0.3× | 0×0.0× | |
| Net debt / EBITDA | 0.2×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $6.75+5.6% | $6.40-13.5% | $7.39+4.2% | $7.09-4.5% | |
| Valuation | |||||
| Market capitalization | $107.34M-54.1% | $89.53M-65.5% | $259.76M-9.9% | $288.17M-73.9% | |
| Price / earnings | 15.7×— | —— | —— | —— | |
| Price / sales | 1×-1.2× | 1.6×-2.0× | 3.6×-1.0× | 4.6×-13.4× | |
| Price / book | 0.8×-1.1× | 0.8×-1.3× | 2.1×-0.2× | 2.3×-6.1× | |
| EV / EBITDA | 6×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are OptimizeRx's profit margins?
- OptimizeRx (OPRX) runs a 70.0% gross margin and a 13.2% operating margin, with a 6.4% net margin.
- Where do OptimizeRx's ratios come from?
- Every ratio is computed from OptimizeRx's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
